Nuvation Bio Inc.
NUVBNext catalyst
NUV-1511
Advanced Solid Tumor
Get an email about NUVB's next catalysts
Track Nuvation Bio (NUVB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
2 upcoming, 1 past
FDA PDUFA Date taletrectinib
SNDA filing. Extracted from: Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
SourceNUV-1511 Phase 2 Est. Readout
Primary completion for NUV-1511 trial (NCT06334432) in Advanced Solid Tumor
SourceMarket Overview
Stock performance and key metrics
Taletrectinib
Non Small Cell Lung Cancer
Crizotinib
Non Small Cell Lung Cancer
safusidenib
Glioma
NUV-1511
Advanced Solid Tumor
AB-106
Non Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Taletrectinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
Crizotinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
safusidenib | Phase 3 | Glioma | - | - |
NUV-1511 | Phase 2 | Advanced Solid Tumor | - | - |
AB-106 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Nuvation Bio Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Nuvation Bio Inc.'s (NUVB) pipeline across Phase 3, Phase 2. Its lead program is Taletrectinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Nuvation Bio Inc.'s next FDA catalyst?→
Nuvation Bio Inc.'s (NUVB) next tracked catalyst is a Phase 2 readout expected March 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NUVB biotech catalysts?→
Add NUVB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Nuvation Bio Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
